The importance of nonpharmacogenetic factors in endocrine therapy

McCowan, C. and Thompson, A.M. (2012) The importance of nonpharmacogenetic factors in endocrine therapy. Pharmacogenomics, 13(6), pp. 721-728. (doi: 10.2217/pgs.12.29)

Full text not currently available from Enlighten.


Nonpharmacogenetic factors may play a key role in the success of oral endocrine therapy for breast cancer. Adherence, defined as following medical advice as well as persistence and duration of use for patients prescribed endocrine therapy, may impact significantly on recurrence and survival. Side effects from tamoxifen or aromatase inhibitors may lead to patients stopping or switching therapy, while comorbidities, consequent coprescribing and patient perceptions may also influence outcomes. Interventions to improve adherence and persistence are required and could have as great an effect on survival as applying pharmacogenetic principles to the endocrine management of breast cancer.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Mccowan, Professor Colin and Thompson, Prof Alastair
Authors: McCowan, C., and Thompson, A.M.
Subjects:R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
Journal Name:Pharmacogenomics
Publisher:Future Medicine
ISSN (Online):1744-8042

University Staff: Request a correction | Enlighten Editors: Update this record